Basel Epidemiology Seminar on

Challenges when studying associations between exposure and outcomes with long latencies

Date and time:

June 23, 2017 14:00-16:30

Venue:

Novartis Pharma AG Auditorium in building WSJ-510 Novartis Campus Basel

Registration:

- Free of charge
- Please register over: http://bes.ceb-institute.org
 (We kindly request also Novartis associates to register for the event.)
- Visitor badges shall be picked up at the main gate, latest 15 min prior to start of the seminar.

Agenda

14:00 – 14:15	Conny Berlin (Novartis) Welcome & Introduction
14:15 – 14:45	Christoph Meier (University Basel) Case study of studying the association between benzodiazepines and Alzheimer's disease
14:45 – 15:15	Sigrid Behr and Daniel Rosenberg (Novartis / Actelion) Assessing long term latencies for newly marketed drugs: mission impossible for the epidemiologist
15:15 – 15:45	Anna Beckmeyer-Borówko (Swiss TPH) The value of population-based studies and their associated biobanks in studying long term exposure effects
15:45 – 16:15	Discussion panel
16:15 – 16:30	Future of BES

What is the Basel Epidemiology Seminar?

(16 December 2016)

The mission of the Basel Epidemiology Seminar (BES) is to facilitate communication among those engaged in epidemiological research and education in the Basel region, and to promote the development and use of epidemiological methods in health research. This is done by organizing joint seminars which serve as a forum for independent scientific exchange on current topics in epidemiology and for discussion of work in progress.

BES is an independent, non-profit forum for discussions between epidemiologists working in the academic, industry or regulatory setting of how to apply epidemiological methods in biological and medical science.

There are two Basel Epidemiology Seminars planned for spring 2017. If you are interested in presenting a topic at BES, please contact sigrid.behr@novartis.com

The Board of Organizers consists of (in alphabetical order):

Sigrid Behr, Novartis Pharma AG

Conny Berlin, Novartis Pharma AG

Heiner C. Bucher, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel and University of Basel

Christoph R. Meier, Basel Pharmacoepidemiology Unit and Hospital Pharmacy, University Hospital Basel and University of Basel

Nicole Probst, Swiss Tropical and Public Health Institute, University of Basel

Daniel Rosenberg, Actelion Pharmaceuticals Ltd.